Novo Nordisk
NVO
1,146 hedge funds and large institutions have $22.1B invested in Novo Nordisk in 2023 Q1 according to their latest regulatory filings, with 175 funds opening new positions, 327 increasing their positions, 428 reducing their positions, and 54 closing their positions.
224% more first-time investments, than exits
New positions opened: 175 | Existing positions closed: 54
30% more call options, than puts
Call options by funds: $296M | Put options by funds: $228M
22% more funds holding in top 10
Funds holding in top 10: 46 → 56 (+10)
15% more capital invested
Capital invested by funds: $19.3B → $22.1B (+$2.84B)
9% more funds holding
Funds holding: 1,049 → 1,146 (+97)
0.07% less ownership
Funds ownership: 16.45% → 16.38% (-0.07%)
24% less repeat investments, than reductions
Existing positions increased: 327 | Existing positions reduced: 428
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$504M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$502M |
| 3 |
Jennison Associates
New York
|
+$126M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$66.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$360M |
| 2 |
Renaissance Technologies
New York
|
-$256M |
| 3 |
Millennium Management
New York
|
-$216M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$163M |
| 5 |
Morgan Stanley
New York
|
-$86.5M |
NVO Hedge Fund Activity: Q1 2023 in Review
1,146 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2023, worth a combined $22.1B — up 15% from $19.3B a quarter earlier.
Buyers outnumbered sellers: 175 funds opened new NVO positions and 54 closed out — a net gain of 121 holders — while 327 added to existing stakes and 428 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $504M. The largest seller was Capital International Investors, cutting an estimated $360M.
- 1,146 institutional investors held Novo Nordisk (NVO) as of Q1 2023, up from 1,049 in Q4 2022.
- Funds reported $22.1B of Novo Nordisk stock for Q1 2023, up 15% quarter-over-quarter.
- 175 funds opened new Novo Nordisk positions in Q1 2023 and 54 closed out, a net change of +121 holders.
- The largest Novo Nordisk buyer in Q1 2023 was T. Rowe Price Associates, an estimated $504M added.
- The largest Novo Nordisk seller in Q1 2023 was Capital International Investors, an estimated $360M sold.
Based on aggregated 13F filings for Q1 2023.